CannBioRx Life Sciences Corp (NASDAQ:ATNFW) — Market Cap & Net Worth
Market Cap & Net Worth: CannBioRx Life Sciences Corp (ATNFW)
CannBioRx Life Sciences Corp (NASDAQ:ATNFW) has a market capitalization of $4.11K ($4.11K) as of June 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #31653 globally and #6250 in its home market, demonstrating a 4200.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying CannBioRx Life Sciences Corp's stock price $0.43 by its total outstanding shares 9551 (9.55K). Review how much debt does CannBioRx Life Sciences Corp carry to assess the company's total debt and financial obligations.
CannBioRx Life Sciences Corp Market Cap History: 2020 to 2025
CannBioRx Life Sciences Corp's market capitalization history from 2020 to 2025. Data shows growth from $3.15K to $4.11K (20.13% CAGR).
CannBioRx Life Sciences Corp Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how CannBioRx Life Sciences Corp's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of ATNFW by Market Capitalization
Companies near CannBioRx Life Sciences Corp in the global market cap rankings as of June 17, 2026.
Key companies related to CannBioRx Life Sciences Corp by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #442 globally with a market cap of $63.33 Billion USD.
- UCB SA (BR:UCB): Ranked #550 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #574 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $453.17 |
| #442 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.33 Billion | $614.73 |
| #550 | UCB SA | BR:UCB | $49.68 Billion | €250.00 |
| #574 | Argen-X | BR:ARGX | $47.14 Billion | €755.80 |
CannBioRx Life Sciences Corp Historical Marketcap From 2020 to 2025
Between 2020 and today, CannBioRx Life Sciences Corp's market cap moved from $3.15K to $ 4.11K, with a yearly change of 20.13%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $4.11K | +4474.47% |
| 2024 | $89.78 | +123.81% |
| 2023 | $40.11 | -92.63% |
| 2022 | $544.41 | -91.86% |
| 2021 | $6.69K | +112.12% |
| 2020 | $3.15K | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of CannBioRx Life Sciences Corp was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.11K USD |
| MoneyControl | $4.11K USD |
| MarketWatch | $4.11K USD |
| marketcap.company | $4.11K USD |
| Reuters | $4.11K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About CannBioRx Life Sciences Corp
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases in the United States. The company product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical t… Read more